Literature DB >> 17230412

Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.

Maria Dorrucci1, Giovanni Rezza, Kholoud Porter, Andrew Phillips.   

Abstract

OBJECTIVE: To determine whether early postseroconversion CD4 cell counts and human immunodeficiency virus (HIV) loads have changed over time.
METHODS: Our analysis was based on 22 cohorts of people with known dates of seroconversion from Europe, Australia, and Canada (Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration). We focused on individuals seroconverting between 1985 and 2002 who had the first CD4 cell count (n=3687) or HIV load (n=1584) measured within 2 years of seroconversion and before antiretroviral use. Linear regression models were used to assess time trends in postseroconversion CD4 cell count and HIV load. Trends in time to key thresholds were also assessed, using survival analysis.
RESULTS: The overall median initial CD4 cell count was 570 cells/ microL (interquartile range [IQR], 413-780 cells/ microL). The median initial HIV load was 35,542 copies/mL (IQR, 7600-153,050 copies/mL; on log(10) scale, 3.9-5.2 log(10) copies/mL). The postseroconversion CD4 cell count changed by an average of -6.33 cells/ microL/year (95% confidence interval [CI], -8.47 to -4.20 cells/ microL/year; P<.001), whereas an increase was observed in log(10) HIV load (+0.044 log(10) copies/mL/year; 95% CI, +0.034 to +0.053 log(10) copies/mL/year). These trends remained after adjusting for potential confounders. The probability of progressing to a CD4 cell count of <500 cells/ microL by 24 months from seroconversion increased from 0.66 (95% CI, 0.63-0.69) for individuals who seroconverted before 1991 to 0.80 (95% CI, 0.75-0.84) for those who seroconverted during 1999-2002.
CONCLUSION: These data suggest that, in Europe, there has been a trend of decrease in the early CD4 cell count and of increase in the early HIV load. Additional research will be necessary to determine whether similar trends exist in other geographical areas.

Entities:  

Mesh:

Year:  2007        PMID: 17230412     DOI: 10.1086/510911

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Authors:  D Noah Sather; Sara Carbonetti; Jenny Kehayia; Zane Kraft; Iliyana Mikell; Johannes F Scheid; Florian Klein; Leonidas Stamatatos
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

2.  Immune-mediated attenuation of HIV-1.

Authors:  Denis R Chopera; Jaclyn K Wright; Mark A Brockman; Zabrina L Brumme
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

3.  The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

Authors:  Christine M Hogan; Victor Degruttola; Xin Sun; Susan A Fiscus; Carlos Del Rio; C Bradley Hare; Martin Markowitz; Elizabeth Connick; Bernard Macatangay; Karen T Tashima; Beatrice Kallungal; Rob Camp; Tia Morton; Eric S Daar; Susan Little
Journal:  J Infect Dis       Date:  2011-12-15       Impact factor: 5.226

4.  Are HIV-positive persons progressing faster after diagnosis over the epidemic?

Authors:  Nancy F Crum-Cianflone; Qian Ren; Lynn E Eberly; Anuradha Ganesan; Amy Weintrob; Vincent Marconi; Robert V Barthel; Brian K Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

5.  Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.

Authors:  Joshua T Herbeck; Viktor Müller; Brandon S Maust; Bruno Ledergerber; Carlo Torti; Simona Di Giambenedetto; Luuk Gras; Huldrych F Günthard; Lisa P Jacobson; James I Mullins; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

6.  Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.

Authors:  Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

7.  Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan.

Authors:  Shigeru Nomura; Noriaki Hosoya; Zabrina L Brumme; Mark A Brockman; Tadashi Kikuchi; Michiko Koga; Hitomi Nakamura; Tomohiko Koibuchi; Takeshi Fujii; Jonathan M Carlson; David Heckerman; Ai Kawana-Tachikawa; Aikichi Iwamoto; Toshiyuki Miura
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 8.  HIV molecular epidemiology: transmission and adaptation to human populations.

Authors:  Zenda Woodman; Carolyn Williamson
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

Review 9.  Current and future antiretroviral treatment options in paediatric HIV infection.

Authors:  Carlo Giaquinto; Erika Morelli; Federica Fregonese; Osvalda Rampon; Martina Penazzato; Anita de Rossi; Ruggero D'Elia
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

10.  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Authors:  Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.